Keyword: Humira

Boehringer just won a skirmish in its high-stakes battle over Humira’s patents, gaining access to documents AbbVie had fought to keep secret.

Humira was only a couple million dollars away from its $20 billion sales goal for 2018, but 2019 will be worse, say AbbVie executives.

The European exodus from branded Humira to biosimilars confirms that AbbVie was was way too optimistic about sales erosion, a Bernstein report reveals.

Could Pfizer's Xeljanz become the 2019 challenger to AbbVie’s Humira TV ad crown?

TV spending on pharma ads continued to rise in 2018, topping $3.73 billion in national TV ad spending, according to data from TV ad tracker iSpot.tv.

What’s a surefire way to get noticed in any field? Beat out a behemoth. And that’s what Eli Lilly’s Taltz has just done in psoriatic arthritis.

Effective immediately, AbbVie is streamlining its executive team to four managers who will serve under CEO Richard Gonzalez.

Joining the list of top 10 pharma TV spenders were a group of new brands including Aimovig, Mavyret and Truvada.

Following a handful of deals for other biosimilar drugmakers, Pfizer decided to settle its Humira patent fight with AbbVie.

Boehringer is hoping for big things from its Humira biosimilar in the U.S.—so much so that it’s giving up on copycat biologics in other countries.